Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Associations between ABCC2 polymorphisms and cisplatin disposition and efficacy.

Clinical pharmacology and therapeutics - 1 Jun 2012

Sprowl J A, Gregorc V, Lazzari C, Mathijssen R H, Loos W J, Sparreboom A

Abstract excerpt

ABCC2 (MRP2, cMOAT) expression has been implicated in cisplatin resistance in vitro. In mice, cisplatin disposition and toxicity were unaffected by Abcc2 knockout (Abcc2−/−). Moreover, in cancer patients (n = 237), cisplatin pharmacokinetics (P > 0.12) and efficacy (P > 0.41) were not associated with seven of the single-nucleotide polymorphisms (SNPs) in ABCC2. These SNPs were also not correlated with ABCC2...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Cisplatin
Share to Kidney Diseases

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Multidrug Resistance-Associated Protein 2

Share to Multidrug Resistance-Associated Proteins

Share to Real-Time Polymerase Chain Reaction

Share to White People

Source

Open in PubMed Open full text

Identifiers

PMID: 22534871
DOI: 10.1038/clpt.2011.330
PMCID: PMC3482956

Genes

ABCC2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Associations between ABCC2 polymorphisms and cisplatin disposition and efficacy.PMID 22534871Read ↗

The role of the human ABCG2 multidrug transporter and its variants in cancer therapy and toxicologySemantic proximity Read ↗

In Vitro Transport Activity and Trafficking of MRP2/ABCC2 Polymorphic Variants.Semantic proximity Read ↗

Single nucleotide polymorphisms in ABCC2 and ABCB1 genes and their clinical impact in physiology and drug response.Semantic proximity Read ↗

Associations of genetic polymorphisms of the transporters organic cation transporter 2 (OCT2), multidrug and toxin extrusion 1 (MATE1), and ATP-binding cassette subfamily C member 2 (ABCC2) with platinum-based chemotherapy response and toxicity in non-small cell lung cancer patients.Semantic proximity Read ↗

A pharmacogenetics study of platinum-based chemotherapy in lung cancer: ABCG2 polymorphism and its genetic interaction with SLC31A1 are associated with response and survivalSemantic proximity Read ↗

Association of ABCC2 polymorphisms with platinum-based chemotherapy response and severe toxicity in non-small cell lung cancer patients.Semantic proximity Read ↗

Interaction of Cisplatin with the human organic cation transporter 2.Semantic proximity Read ↗

Two polymorphic variants of ABCC1 selectively alter drug resistance and inhibitor sensitivity of the multidrug and organic anion transporter multidrug resistance protein 1.Semantic proximity Read ↗

Increased ABCC2 expression predicts cisplatin resistance in non‐small cell lung cancerSemantic proximity Read ↗

ABCC2 polymorphisms and survival in the Princess Margaret cohort study and the NCIC clinical trials group BR.24 trial of platinum-treated advanced stage non-small cell lung cancer patients.Semantic proximity Read ↗

Lack of association between ABCC2 gene variants and treatment response in epilepsy.Semantic proximity Read ↗

Contribution of organic cation transporter 2 (OCT2) to cisplatin-induced nephrotoxicity.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.